ArriVent BioPharma Strengthens Board Alignment with New Director Stock Awards

Rhea-AI Filing Summary

Form 4 filing reveals that Kristine Peterson, Director at ArriVent BioPharma, was granted 15,502 non-qualified stock options on June 18, 2025. The options have the following key terms:

• Exercise price set at $24.89 per share
• Exercisable starting June 18, 2026
• Expiration date of June 17, 2035
• Underlying security is ArriVent BioPharma common stock

The options were acquired at a price of $0.00, indicating a compensation grant. The filing was signed by James Kastenmayer as attorney-in-fact for Peterson on June 20, 2025. This equity compensation aligns the director's interests with shareholders through long-term stock ownership potential.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peterson Kristine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	15,502	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 15,502 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Kristine

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD SUITE 100

(Street)

NEWTOWN SQUARE PA 19073

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$24.89	06/18/2025		A		15,502		06/18/2026	06/17/2035	Common Stock	15,502	$0.00	15,502	D

Explanation of Responses:

	By: /s/ James Kastenmayer, Attorney-in-Fact for Kristine Peterson	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did AVBP director Kristine Peterson receive on June 18, 2025?

Kristine Peterson received 15,502 non-qualified stock options with an exercise price of $24.89 per share. These options are exercisable starting June 18, 2026 and expire on June 17, 2035.

What is the exercise price of AVBP stock options granted to Kristine Peterson?

The non-qualified stock options were granted with an exercise price of $24.89 per share.

When do Kristine Peterson's AVBP stock options expire?

The stock options granted to Kristine Peterson expire on June 17, 2035, approximately 10 years from the grant date.

What position does Kristine Peterson hold at AVBP?

According to the Form 4 filing, Kristine Peterson serves as a Director of ArriVent BioPharma, Inc. (AVBP).

When can Kristine Peterson exercise her AVBP stock options?

The stock options become exercisable on June 18, 2026, one year after the grant date of June 18, 2025.